{
    "nct_id": "NCT01047579",
    "title": "A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon\u00ae Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2017-02-22",
    "description_brief": "This study is designed to evaluate caregiver preference for Exelon\u00ae patch (target patch size 10 cm\u00b2) treatment in patients with Alzheimer's disease (MMSE 10-26) who were under cholinesterase inhibitor treatment and experienced adverse event/s in a community setting.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "OTHER",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Rivastigmine (Exelon\u00ae patch)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests Exelon\u00ae patch (rivastigmine transdermal). Rivastigmine is a centrally-acting acetylcholinesterase (cholinesterase) inhibitor that increases cholinergic neurotransmission and is used to improve cognitive symptoms in Alzheimer\u2019s disease \u2014 a symptomatic (cognitive-enhancing) treatment rather than a biologic or a disease-modifying agent. \ue200cite\ue202turn0search3\ue202turn0search7\ue201",
        "Act (key extracted details and sources): The intervention named in the protocol is Exelon\u00ae patch (rivastigmine transdermal; target patch size 10 cm\u00b2) given to patients with AD (MMSE 10\u201326) in an open-label caregiver-preference, safety and tolerability study \u2014 i.e., a trial of a small-molecule transdermal cholinesterase inhibitor focusing on symptomatic benefit and tolerability. Regulatory/label and product information for Exelon\u00ae Patch support this description. \ue200cite\ue202turn0search8\ue202turn0search0\ue201",
        "Reflect: Classification = \"cognitive enhancer\". Rationale: rivastigmine is a small-molecule cholinesterase inhibitor approved to treat cognitive/dementia symptoms in Alzheimer\u2019s disease and is not a monoclonal antibody, vaccine, or a drug that targets amyloid or tau pathology (so it does not meet the definitions for a disease-targeted biologic or disease-targeted small molecule). No ambiguity in the trial description changes this classification. \ue200cite\ue202turn0search6\ue202turn0search1\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests Exelon\u00ae patch (rivastigmine transdermal), a cholinesterase inhibitor that increases acetylcholine levels and thereby enhances cholinergic neurotransmission to improve cognitive symptoms in Alzheimer\u2019s disease \u2014 this is modulation of a neurotransmitter system rather than a disease-modifying approach. \ue200cite\ue202turn0search6\ue202turn0search2\ue201",
        "Act: Key extracted details \u2014 intervention: Exelon\u00ae patch (rivastigmine transdermal, target/maintenance dose 9.5 mg/24 h delivered from a 10 cm\u00b2 patch in many studies); indication: symptomatic treatment of mild\u2013moderate (and in some approvals, severe) Alzheimer\u2019s dementia; mechanism: reversible inhibition of acetylcholinesterase (and butyrylcholinesterase) leading to increased acetylcholine. These details support classification under neurotransmitter modulation. \ue200cite\ue202turn0search3\ue202turn0search4\ue202turn0search8\ue201",
        "Reflect: Classification = 'D) Neurotransmitter Receptors'. Rationale: rivastigmine acts by inhibiting cholinesterase enzymes to augment cholinergic neurotransmission (a neurotransmitter-targeted symptomatic cognitive enhancer), which aligns with CADRO\u2019s Neurotransmitter Receptors category. There is no indication in the trial description that the drug targets amyloid, tau, inflammation, proteostasis, vasculature, or multiple distinct disease pathways, so 'D' is the most specific fit. \ue200cite\ue202turn0search6\ue202turn0search2\ue201",
        "Web search results (sources used):",
        "- Novartis Exelon Patch FDA/label and press information (indications, patch dosing and safety). \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "- Mayo Clinic drug monograph: rivastigmine transdermal description and mechanism (acetylcholinesterase inhibitor; symptomatic cognitive benefit). \ue200cite\ue202turn0search2\ue201",
        "- PubMed reviews describing rivastigmine patch dosing, 10 cm\u00b2 (9.5 mg/24 h) patch and clinical trial data. \ue200cite\ue202turn0search3\ue202turn0search4\ue201",
        "- StatPearls/NCBI summary of rivastigmine mechanism (AChE and BuChE inhibition) and formulations. \ue200cite\ue202turn0search6\ue201",
        "- CenterWatch / product summary describing mechanism and clinical use. \ue200cite\ue202turn0search8\ue201"
    ]
}